US67080M1036
US67080M1036
Nurix Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 31.05.2026 | Q1 '26 28.02.2026 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 2.32B EUR | 1.84B EUR | 1.65B EUR |
Enterprise Value | 1.92B EUR | 1.83B EUR | 1.64B EUR |
Valuation Multiples | |||
Trailing P/E | -- | -- | -- |
Forward P/E | -20.98x | -- | -- |
Price to Sales | 63.09x | 50.09x | 23.01x |
Price to Book | 5.76x | 4.57x | 3.43x |
EV/Revenue | 52.21x | 49.83x | 22.83x |
EV/EBITDA | -5.44x | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- |
EV/FCF | -- | -- | -- |
FCF Yield | -7.1% | -16.53% | -16.46% |